Dragon Pharmaceutical Inc. has developed a new biotech production process for 7-ACA, an intermediate for Cephalosporin antibiotics. The new process replaces a chemical manufacturing technique that involved solvents, toxic waste and extreme temperatures.  Because the process involved many expenses that are no longer necessary, Dragon forecasts its product will now be more competitive than before. We look at the process and at the company.  More details...

Stock Symbol: (OTCBB: DRUG)